The U.S. District Court of Delaware has found that both Natera and CareDx engaged in false advertising.
According to the jury, CareDx made "false statements about its involvement in and funding of a scientific publication ... [and] misled investors and physicians regarding CareDx's drafting and funding of a paper that they claimed was independent, when it was not," Natera said in a statement.
In other litigation between the two firms, a federal court has thrown out all patents that CareDx asserted against Natera, the company said.
